力生制药
(002393)
| 流通市值：38.04亿 | | | 总市值：39.06亿 |
| 流通股本：3.00亿 | | | 总股本：3.08亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 888,015,988.08 | 641,633,361.63 | 332,282,846.72 | 1,392,014,298.29 |
| 营业总成本 | 791,647,478.14 | 545,482,254.7 | 275,933,687.7 | 1,237,397,826.21 |
| 其他经营收益 | | | | |
| 营业利润 | 98,617,376.67 | 94,900,305.19 | 62,377,868.72 | 469,130,803.95 |
| 利润总额 | 96,947,419.45 | 95,012,674.95 | 62,308,871.84 | 455,605,151.75 |
| 净利润 | 81,960,358.2 | 80,075,919.72 | 53,065,562.17 | 422,726,444.63 |
| 每股收益 | | | | |
| 其他综合收益 | 1,084,900.74 | 769,832.25 | 2,438,356.16 | -412,435,477.98 |
| 综合收益总额 | 83,045,258.94 | 80,845,751.97 | 55,503,918.33 | 10,290,966.65 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 3,089,585,013.05 | 3,171,108,131.27 | 3,298,834,982.1 | 3,329,703,353.16 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,227,554,369.61 | 2,177,094,908.46 | 2,234,220,394.59 | 2,254,704,645.15 |
| 资产总计 | 5,317,139,382.66 | 5,348,203,039.73 | 5,533,055,376.69 | 5,584,407,998.31 |
| 流动负债: | | | | |
| 流动负债合计 | 634,147,287.33 | 665,864,253.78 | 729,273,910.5 | 761,731,671.75 |
| 非流动负债: | | | | |
| 非流动负债合计 | 160,265,532.37 | 163,122,692.33 | 164,299,407.36 | 162,127,063.87 |
| 负债合计 | 794,412,819.7 | 828,986,946.11 | 893,573,317.86 | 923,858,735.62 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,489,233,811.22 | 4,487,473,439.01 | 4,605,756,501.87 | 4,628,056,357.77 |
| 股东权益合计 | 4,522,726,562.96 | 4,519,216,093.62 | 4,639,482,058.83 | 4,660,549,262.69 |
| 负债和股东权益合计 | 5,317,139,382.66 | 5,348,203,039.73 | 5,533,055,376.69 | 5,584,407,998.31 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 893,505,854.83 | 616,339,725.2 | 332,283,803.41 | 1,596,121,092.44 |
| 经营活动现金流出小计 | 954,717,769.77 | 660,531,261.67 | 331,295,083.1 | 1,348,624,441.73 |
| 经营活动产生的现金流量净额 | -61,211,914.94 | -44,191,536.47 | 988,720.31 | 247,496,650.71 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,424,134,510.74 | 1,117,250,676.21 | 493,930,470.13 | 3,317,751,726.56 |
| 投资活动现金流出小计 | 1,425,481,479.6 | 1,101,292,932.86 | 464,390,851.74 | 3,485,038,659.59 |
| 投资活动产生的现金流量净额 | -1,346,968.86 | 15,957,743.35 | 29,539,618.39 | -167,286,933.03 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,985,993.07 | 1,985,993.07 | - | 94,048,560.8 |
| 筹资活动现金流出小计 | 262,463,581.86 | 255,782,548.53 | 77,509,807.08 | 232,185,152.48 |
| 筹资活动产生的现金流量净额 | -260,477,588.79 | -253,796,555.46 | -77,509,807.08 | -138,136,591.68 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | -2,566.09 |
| 现金及现金等价物净增加额 | -323,036,472.59 | -282,030,348.58 | -46,981,468.38 | -57,929,440.09 |
| 期末现金及现金等价物余额 | 1,214,203,831.11 | 1,255,205,265.04 | 1,490,256,115.26 | 1,537,235,613.62 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -282,030,348.58 | - | -57,929,440.09 |